Diabetes alone should not be a reason for withholding adjuvant chemotherapy for stage III colon cancer by van Waalwijk, Maren A. et al.
19
© 2011 The Authors. This is an open-access article and may be freely copied, distributed, transmitted and adapted by anyone provided the original author, 
citation details and publisher are acknowledged. The work is made available under the Creative Commons Attribution Non-Commercial Licence.
 Published by Swiss Medical Press GmbH | www.swissmedicalpress.com
Journal of Comorbidity 2011;1:19–27
Original article
Diabetes alone should not be a reason for withholding adjuvant 
chemotherapy for stage III colon cancer
Maren A. van Waalwijk1, Saskia A. M. van de Schans2, Harm R. Haak1, 
Martine Extermann3, Wouter M. W. Dercksen1, Maryska L. G. Janssen-Heijnen2,4,∗
1Department of Internal Medicine, Máxima Medical Centre, Eindhoven, The Netherlands; 2Department of Research, 
Eindhoven Cancer Registry, Comprehensive Cancer Centre South, Eindhoven, The Netherlands; 3Moffi tt Cancer 
Center, Department of Senior Adult Oncology, University of South Florida, Tampa, FL, USA; 4Department of Clinical 
Epidemiology, VieCuri Medical Centre Venlo, The Netherlands
Abstract
Background: With increasing prevalence of diabetes mellitus and colon cancer, the number of patients suffering 
from both diseases is growing, and physicians are being faced with complicated treatment decisions. Objective: 
To investigate the association between diabetes and treatment/course of stage III colon cancer and the association 
between colon cancer and course of diabetes. Materials and Methods: Additional information was collected 
from the medical records of all patients with both stage III colon cancer and diabetes (n=201) and a random 
sample of stage III colon cancer patients without diabetes (n=206) in the area of the population-based Eindhoven 
Cancer Registry (1998–2007). Results: Colon cancer patients without diabetes were more likely to receive adju-
vant chemotherapy compared with diabetic colon cancer patients (OR 1.8; 95% CI 1.2–2.7). After adjustment for 
age, this difference was borderline signifi cant (OR 1.6; 95% CI 1.0–2.6). Diabetic patients did not have: signifi cantly 
more side-effects from surgery or adjuvant chemotherapy; more recurrence from colon cancer; signifi cantly shorter 
time interval until recurrence; or a poorer disease-free survival or overall survival. Age and withholding of adjuvant 
chemotherapy were most predictive of all-cause mortality. After colon cancer diagnosis, the dose of antiglycaemic 
medications was increased in 22% of diabetic patients, resulting in signifi cantly lower glycaemic indexes than before 
colon cancer diagnosis. Conclusions: Since diabetic patients did not have more side-effects of adjuvant chemo-
therapy, and adjuvant chemotherapy had a positive effect on survival for both patients with and without diabetes, 
diabetes alone should not be a reason for withholding adjuvant chemotherapy.
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Introduction
Due to ageing of the population and the increasing 
prevalence of obesity, the incidence of diabetes melli-
tus is rising [1, 2], and, at the same time, an increase 
in the incidence of colon cancer is also being observed. 
In the Netherlands, for example, the incidence rate 
[European standardized rate (ESR)] of colon cancer 
increased from 29 in 1989 to 36 per 100,000 person-
years in 2006 [3]. Therefore, the number of patients 
with both colon cancer and diabetes is increasing. Pre-
vious studies have shown a worse prognosis for colon 
cancer patients with diabetes compared with those with-
out diabetes [4–7]. Several factors might be responsible 
for this effect: the increased risk of death due to diabetes 
or accompanying comorbid conditions; neglect of treat-
ment of diabetes; more contraindications for anticancer 
20  M. A. van Waalwijk et al.
© 2011 The Authors
 Published by Swiss Medical Press GmbH | www.swissmedicalpress.com Journal of Comorbidity 2011;1:19–27
treatment; lower effectiveness of adjuvant chemotherapy 
in diabetic patients; or a higher rate of treatment-related 
complications. 
The current standard treatment for stage III colon 
cancer is surgery with adjuvant chemotherapy. However, 
as shown in a previous study, colon cancer patients with 
diabetes received adjuvant chemotherapy less frequently 
compared with those without diabetes [8]. This implies 
that colon cancer patients with diabetes might have a 
poorer prognosis due to them not receiving appropri-
ate treatment for their colon cancer. On the other hand, 
diabetic patients might be more prone to chemothe-
rapy-related toxicity because of the high prevalence of 
pre-existing comorbid conditions in this group. Only a 
few studies have analysed the effect of diabetes on colon 
cancer treatment and treatment outcome [5, 6, 8]. Even 
less is known about the effect of colon cancer on the 
course and outcome of diabetes.
We studied the association of diabetes with the 
administration of adjuvant chemotherapy, dose, treat-
ment-related toxicity, and outcome of treatment in stage 
III colon cancer patients. In addition, the association 
between colon cancer and its treatment, on the one hand, 
and the course of diabetes, on the other, are described.
Materials and Methods
Study population and data collection
Data from patients with stage III colon cancer diagnosed 
in the registration area of the Eindhoven Cancer Regis-
try were used. This registry records data on all patients 
with newly diagnosed cancer in the southern part of 
the Netherlands (an area with 2.4 million inhabitants, 
10 general hospitals, and two radiotherapy institutes). 
Registration clerks actively collect data on diagnosis, 
topography, histology, stage, and information about ini-
tial treatment (delivered within 6 months from diagnosis) 
from hospital medical records. Since 1993, the presence 
of comorbidity at the time of diagnosis has also been 
documented. Specifi c comorbid conditions were regis-
tered as dichotomous variables (Yes/No), according to 
the medical history of the patient, use of relevant drugs, 
and diagnostic work-up. Conditions included chronic 
obstructive pulmonary disease (COPD), cardiovascular 
disease (CVD), peripheral arterial disease, cerebrovas-
cular disease, other malignancies, and hypertension, as 
described in a previous publication [9]. In our study, the 
specifi c comorbid condition (CVD) and the total amount 
of comorbidities (minus diabetes) were used to study the 
different patient characterizations between colon cancer 
patients with and without diabetes (Table 1). Further-
more, the number of comorbidities (minus diabetes) was 
analysed in a multivariable survival analysis. The specifi c 
comorbidities of CVD and COPD were evaluated in the 
subgroup analysis of patients who died before adjuvant 
chemotherapy could be administered.
CVD included: any previous myocardial infarction; 
current treatment for cardiac insuffi ciency, angina pec-
toris, and peripheral arterial disease; previous coronary 
artery bypass graft surgery; and current or previous treat-
ment for cerebrovascular disease.
We selected all the colon cancer patients with stage III 
disease, who were diagnosed between 1998 and 2007, 
aged 50 years and older, and who had undergone surgi-
cal treatment. For this study, we included all patients 
with both stage III colon cancer and diabetes (n=236) 
and a random sample of stage III colon cancer patients 
without diabetes (n=240). 
Additional information on patient characteristics, 
treatment, and outcome was collected from the medical 
records. The medical record is regarded as the most com-
plete source of information on a patient’s past and current 
health status [10]. Patient characteristics included infor-
mation on overall performance according to the Eastern 
Cooperative Oncology Group (ECOG) performance 
scale [11], body mass index (BMI), diabetes status, and 
smoking status. ECOG score was registered in two ways. 
If present, we used the World Health Organization 
(WHO) performance scale, ECOG score or a specifi c 
remark describing performance status recorded by the 
specialist. If not present, we estimated the ECOG score 
from the text in the medical record. BMI was classifi ed 
as underweight (<18 kg/m2), normal (18–25 kg/m2), 
overweight (26–30 kg/m2), and obese (>30 kg/m2). 
Information about diabetes status was collected, includ-
ing type of diabetes, year of onset, and the existence of 
diabetic complications. Type of diabetes was directly 
registered from the medical record. When data were incon-
sistent or confl icting (e.g. patients registered as having type 
2 diabetes with a low BMI or diagnosed at a young age) 
diabetes status was recorded as unknown. We registered 
microvascular complications (retinopathy, nephropathy, 
and neuropathy) and macrovascular complications (coro-
nary diseases and peripheral arterial disease) at the time 
of colon cancer diagnosis. Macrovascular complications 
were recorded as diabetes-related if they occurred after the 
onset of diabetes. Duration of diabetes was defi ned as from 
year of onset of diabetes to diagnosis of colon cancer. To 
study the effect of colon cancer on the course of diabe-
tes, haemoglobin A1c (HbA1c) regulation and the use of 
medication were registered before and after treatment of 
colon cancer. In the Netherlands, most diabetic patients 
are treated by their general practitioner (GP). We there-
fore contacted the patients’ GPs if any of this information 
was missing or incomplete in the medical record. 
Detailed information on treatment of colon cancer 
was collected, including adjuvant chemotherapy, type of 
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adjuvant chemotherapy, reason for withholding adjuvant 
chemotherapy, number and length of cycles, possible 
dose adjustments, and reason for dose adjustments. In 
addition, treatment complications (from surgery or 
adjuvant chemotherapy) were registered. Toxicity was 
recorded using the Common Toxicity Criteria [11]. 
Only serious side-effects (Grade 3 or 4 toxicity) were 
registered.
To study the effect of diabetes on the prognosis of 
colon cancer, we collected information on recurrence 
rate and vital status. Recurrence was defi ned as the 
existence of local recurrence, metastatic disease, or 
both, as noted in the medical record. Time to recurrence 
was defi ned as the time from colon cancer diagnosis to 
recurrence.
Information about vital status was actively obtained 
from the municipal personal records database on Janu-
ary 2010. Overall survival (OS) was defi ned as the 
time from diagnosis to death or the end of follow-up. 
Disease-free survival was defi ned as the time from diagnosis 
to recurrence, death, or end of follow-up, whichever came 
fi rst. Patients who were still alive at the end of follow-up 
were censored on the date of last follow-up.
A total of 476 patients who met our inclusion crite-
ria were selected from the Eindhoven Cancer Registry 
database. The medical records were missing or did not 
contain suffi cient data for 69 of these patients (35 patients 
with diabetes, 34 patients without diabetes), so they were 
excluded from the study. The excluded patients did not 
differ in age, number of comorbid conditions, or number 
of deaths compared with patients who were included. 
This brought the total number of patients included in 
our study to 407. We handled the data from our can-
cer registry according to the offi cially recognized code 
of conduct ‘Use of data in health research’ [12]. Patient 
consent was not required as general information from 
the cancer registry was at the hospital level and the data 
were made anonymous.
Table 1 Baseline characteristics according to diabetes status.
Characteristic Frequency (%) p value
Diabetes (n=201) No diabetes (n=206)
Age (years)
50–64
65–69
70–74
75–84
≥85
39 (19)
29 (14)
44 (22)
77 (38)
12 (6)
57 (28)
30 (15)
47 (23)
56 (27)
16 (8)
0.12
Gender
Male
Female
85 (42)
116 (58)
96 (47)
110 (53)
0.38
BMI (kg/m2)
<18
18–25
26–30
≥31
Unknown
1 (<1)
67 (33)
55 (27)
34 (17)
44 (22)
1 (<1)
94 (46)
51 (25)
15 (7)
45 (22)
0.02
ECOG performance status score
0+1
≥2
118 (62)
71 (38)
147 (75)
50 (25)
<0.01*
Smoking status
Yes
No
Stopped
Unknown
19 (9)
60 (30)
79 (39)
43 (21)
19 (9)
55 (27)
74 (36)
58 (28)
0.47
Comorbid conditions (n)
 (DM not included)
0
1
2
≥3
39 (19)
65 (32)
58 (29)
39 (19)
80 (39)
68 (33)
39 (19)
19 (9)
<0.01
Cardiovascular disease
Yes
No
89 (44)
112 (56)
60 (29)
146 (71)
<0.01
∗
p value was determined without missing data. BMI, body mass index; DM, diabetes mellitus; ECOG, European Cooperative Oncology Group.
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Statistical analyses
First, we determined whether characteristics differed sig-
nifi cantly between diabetic and non-diabetic patients. 
Second, colon cancer patients with and without diabetes 
were compared with respect to the proportion of patients 
receiving adjuvant chemotherapy, regimen, dose reduc-
tion, and reason for dose reduction. Furthermore, we 
compared both groups with respect to treatment response, 
postoperative complications (as a proportion of all patients 
who underwent surgery), and toxicity from adjuvant che-
motherapy (as a proportion of all patients who received 
adjuvant chemotherapy). To analyse the aforementioned 
associations, we used percentages and the Chi-square test. 
Because diabetic patients differed signifi cantly in age, 
comorbidity, and BMI, we adjusted for these variables in 
multivariable logistic regression analyses. 
Hazard ratios (HR) for all-cause mortality were esti-
mated for diabetic patients, with non-diabetic patients 
as a reference. To evaluate whether a possible difference 
in survival between diabetic and non-diabetic patients 
was confounded by differences in patient character-
istics or treatment, we used a Cox regression analysis 
including age, ECOG score, gender, adjuvant chemo-
therapy administration, and comorbidity. We also tested 
for interaction with age or adjuvant chemotherapy. To 
evaluate the infl uence of the severity of diabetes, we 
analysed survival for different HbA1c groups and dura-
tion of diabetes. We also evaluated the prognostic effect 
of using metformin or insulin for diabetes. 
In addition, the association between colon cancer and 
treatment/course of diabetes was analysed by evaluat-
ing changes in the treatment of diabetes and glycaemic 
control before and after colon cancer diagnosis. For the 
mean HbA1c before and after colon cancer diagnosis, 
we used the paired t-test. The SAS computer package 
(version 9.1) was used for all statistical analyses (SAS 
Institute Inc., Cary, North Carolina, USA, 1999). 
Results
Table 1 shows the baseline characteristics of patients 
according to diabetes status. Patients with diabetes were 
slightly older than patients without diabetes, but this 
was not statistically signifi cant (p=0.12). BMI was sig-
nifi cantly higher in diabetic patients (p=0.02). Diabetic 
patients had a signifi cantly poorer performance status 
(p<0.01) and signifi cantly more comorbid conditions 
(p<0.01), especially CVD (p<0.01).
Adjuvant chemotherapy
In all, 208 patients (51%) received adjuvant chemother-
apy. Fifty-nine percent of the adjuvant chemotherapeutic 
regimens included 5-fl uorouracil (5-FU) and leucovorin. 
Other regimens were capecitabine as monotherapy or 
in combination with oxaliplatin (20%), or 5-FU, leu-
covorin, and oxaliplatin according to the FOLFOX 
scheme (12%). The distribution of regimens did not 
differ for patients with or without diabetes. Sixty per-
cent of patients without diabetes versus 42% of those 
with diabetes received adjuvant chemotherapy [odds 
ratio (OR) 1.8; 95% confi dence interval (CI) 1.2–27]. 
After adjustment for age, this difference was only bor-
derline signifi cant (OR 1.6; 95% CI 1.0–2.6). Age was 
not an effect modifi er. Therefore, the effect of diabetes 
on receiving adjuvant chemotherapy was not statistically 
different in the two age groups. Median age was 67 years 
for patients receiving adjuvant chemotherapy versus 77 
years for patients not receiving adjuvant chemotherapy. 
This was similar for patients with and without diabetes. 
Reasons given for withholding adjuvant 
chemotherapy
Advanced age was the most common reason given for with-
holding adjuvant chemotherapy (22% for patients with 
diabetes and 29% for those without diabetes) (Table 2). 
Patient’s choice was the second most common reason (17 
and 15% for those with and without diabetes, respec-
tively). Comorbidity was more often a reason given for 
withholding adjuvant chemotherapy in diabetic patients 
compared with non-diabetic patients (15 vs. 2%, respec-
tively). Twenty-one patients had already died before 
adjuvant chemotherapy could be commenced. This 
was the most likely reason why these patients did not 
receive adjuvant chemotherapy (11% in diabetic patients 
and 10% in non-diabetic patients). For patients who 
had died before adjuvant chemotherapy could be com-
menced, more had diabetes [13 vs. 8 patients (62 vs. 
38%), respectively], pulmonary disease [4 vs. 45 patients 
(19 vs. 12%), respectively] and CVD [10 vs. 139 patients 
(48 vs. 36%), respectively], compared with those who 
had started adjuvant chemotherapy.
Table 2 Reason given for withholding adjuvant chemotherapy accor-
ding to diabetes status.
Reason Frequency (%)
Diabetes (n=116) No diabetes (n=82)
Advanced age 25 (22) 24 (29)
Overall performance status 12 (10) 9 (11)
Patient’s choice 20 (17) 12 (15)
Comorbidity 17 (15) 2 (2)
Patient died before 
 receiving chemotherapy
13 (11) 8 (10)
Other 3 (4) 0 (0)
Unknown 26 (22) 27 (33)
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Adaptations to adjuvant chemotherapy
The dose of adjuvant chemotherapy was reduced in 
89 of 208 patients (43%) receiving adjuvant chemo-
therapy. This was similar for diabetic and non-diabetic 
patients. The most important reasons given for dose 
reductions were gastrointestinal side-effects [29 patients 
(33%)] and neurological side-effects [18 patients (20%)]. 
There were no differences between diabetic and non-
diabetic patients with respect to reasons given for dose 
reductions.
Complications
Diabetic patients tended to have more complications 
than non-diabetic patients from surgery [62 vs. 48 
patients (31 vs. 23%), respectively; p=0.09]. There were 
no signifi cant differences in total toxicity from adju-
vant chemotherapy [31 diabetic patients (15%) versus 41 
non-diabetic patients (20%); p=0.19] or type of toxicity 
(neuropathy or infections). However, more diabetic than 
non-diabetic patients were admitted to the intensive 
care unit because of surgical or adjuvant chemotherapy
-related complications [24 diabetic patients (12%) vs. 
8 non-diabetic patients (4%); p<0.01]. 
Association between diabetes and recurrence 
of colon cancer 
In 164 patients (42%), a recurrence of colon cancer 
occurred (Table 3). This occurred in 75 diabetic patients 
(39%) and in 89 non-diabetic patients (45%) (p=0.26). 
Seventy-nine of the patients who received adjuvant che-
motherapy (39%) had recurrent disease. Again, there 
was no signifi cant difference between patients with or 
without diabetes. There was no statistically signifi cant 
difference in median time to recurrence in diabetic 
versus non-diabetic patients (19 vs. 22 months, respec-
tively; p=0.45). There was also no signifi cant difference 
in median time to recurrence between patients who 
received adjuvant chemotherapy and those who did not 
(19 vs. 21 months, respectively; p=0.41).
Association between diabetes and survival of colon 
cancer patients
At the end of follow-up, 201 patients (49%) were still 
alive, 205 patients (50%) had died and one was lost to 
follow-up. Five-year OS was slightly better for non-di-
abetic patients (50%) compared with diabetic patients 
(42%) (borderline signifi cant, p=0.05) (Figure 1). Table 4 
shows univariate and multivariable survival analyses. 
In the univariate analysis, the HR for all-cause mor-
tality for diabetic patients versus non-diabetic patients 
was 1.3 (borderline signifi cant: 95% CI 0.99–1.72). 
However, after adjustment for other prognostic param-
eters, this effect disappeared. There was no interaction 
with age or adjuvant chemotherapy. CVD alone did 
not infl uence survival. Patients who received adjuvant 
chemotherapy were signifi cantly less likely to die than 
those who did not receive adjuvant chemotherapy, even 
after adjustment for age, diabetes status, ECOG score, 
gender, and number of comorbid conditions (HR 
0.52). We also calculated HR for all-cause mortality 
for different parameters of diabetes. Mortality was not 
signifi cantly associated with glycaemic control, dura-
tion of diabetes, use of metformin, or use of insulin 
(Table 5).
Disease-free survival was calculated for diabetic 
patients versus non-diabetic patients (Figure 2). There 
was no signifi cant difference between these groups 
(p=0.1), HR 1.24 (95% CI: 0.95–1.6) in the multi-
variate analysis. Disease-free survival was signifi cantly 
longer for patients receiving adjuvant chemotherapy 
(p<0.01), HR 0.40 (95% CI: 0.30–0.52) in the multi-
variate analysis.
Infl uence of colon cancer on diabetes
At the time of colon cancer diagnosis, 192 patients had 
type 2 diabetes, and one patient had confi rmed type 1 
diabetes. Diabetes status was unknown for eight patients. 
Another 11 patients (5%) developed diabetes after colon 
cancer diagnosis. Median duration from diabetes to 
colon cancer diagnosis was 5.5 years with a minimum 
duration of 2 months and a maximum duration of 50 
years. Information on glycaemic control was available 
for 90 patients. Mean HbA1c 1 year before diagnosis of 
colon cancer was 7.6% and 1 year after diagnosis was 
7.2% (p<0.01). Mean decrease in HbA1c was 0.38%. 
Before colon cancer diagnosis, 135 patients (67%) were 
treated with an oral antiglycaemic agent (Table 6). Sev-
enty-six patients (50%) were treated with metformin as 
monotherapy or in combination therapy with another 
oral antiglycaemic agent. One year after colon cancer 
diagnosis, one patient who formerly used an oral antigly-
caemic agent, switched to insulin. Twenty-two patients 
Table 3 Recurrence rate of colon cancer in patients with and without 
adjuvant chemotherapy treatment according to diabetes status.∗
Rate (%) p value
Diabetes No diabetes
Chemotherapy  28/82 (34) 51/121 (42) 0.25
No chemotherapy 47/108 (44)  38/76 (50) 0.39
∗
Recurrence status was unknown in 11 diabetic patients and in nine non-
diabetic patients. Recurrence percentage was calculated as the number of 
patients with recurrence divided by the total number of patients at risk 
of recurrence in the respective group.
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Of all 201 diabetic patients, 80 (40%) had one or more 
diabetes-related complications at the time of colon can-
cer diagnosis. In this group, 27 patients (34%) had only 
microvascular complications and 20 patients (25%) had 
microvascular and macrovascular complications. After 
colon cancer diagnosis and treatment, eight new patients 
had developed microvascular and/or macrovascular 
complications.
Discussion
This population-based study revealed that stage III colon 
cancer patients with diabetes had slightly more post-
operative complications and were slightly less likely to 
receive adjuvant chemotherapy than their non-diabetic 
Table 4 Hazard ratio for all-cause mortality in all patients with colon cancer following univariate and multivariate analyses.
Variable HR (95% CI)
Univariate analysis Multivariate analysis
Diabetes vs. no diabetes 1.31 (0.99–1.72) 0.99 (0.74–1.32)
Age at time of colon cancer diagnosis 1.05 (1.04–1.07) 1.02 (1.0–1.04)
ECOG score ≥2 vs. 0+1 1.99 (1.50–2.65) 1.37 (0.99–1.89)
Chemotherapy vs. no chemotherapy 0.37 (0.28–0.49) 0.52 (0.35–0.76)
Male vs. female 0.85 (0.64–1.13) 1.03 (0.77–1.39)
Comorbidity frequency 
1 vs. 0 1.28 (0.90–1.83) 1.20 (0.83–1.75)
2 vs. 0 1.15 (0.77–1.72) 0.87 (0.86–1.33)
≥3 vs. 0 2.07 (1.36–3.17) 1.31 (0.83–2.07)
CI, confi dence interval; ECOG, European Cooperative Oncology Group; HR, hazard ratio.
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Figure 1 Overall survival for colon cancer patients with and without diabetes, according to chemotherapy.
Table 5 Hazard ratio for all-cause mortality in diabetic patients with 
colon cancer.
Variable Univariate analysis
HR 95% CI
Duration of diabetes 1–10 years vs. 
 >10 years
0.86 0.54–1.38
Mean HbA1c (%)
<6.5 vs. 6.5–7.5 1.03 0.57–1.86
7.6–9.0 vs. 6.5–7.5 1.11 0.65–1.88
≥9.1 vs. 6.5–7.5 0.79 0.35–1.76
Use of insulin vs. no insulin 0.91 0.58–1.41
Use of metformin vs. no metformin 0.73 0.49–1.11
CI, confi dence interval; HR, hazard ratio.
(16%) who used oral antiglycaemic agents received 
a higher dose and 14 patients (33%) who used insulin 
received a higher dose after colon cancer diagnosis. 
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counterparts. Diabetes had no independent infl uence on 
recurrence or survival. As suspected, patients both with 
or without diabetes who received adjuvant chemother-
apy survived longer, even after adjustment for patient 
characteristics. One year after surgery for colon cancer, 
diabetic patients had lower HbA1c than before colon 
cancer diagnosis. 
Only a few other studies have investigated the asso-
ciation between diabetes mellitus and chemotherapy. 
Gross and colleagues also found that diabetic patients 
were less likely to receive adjuvant chemotherapy for 
stage III colon cancer, even after adjustment for patient 
characteristics and cancer characteristics [8]. In accord-
ance with other studies, we found that high age was the 
most common reason given for withholding adjuvant 
chemotherapy, whereas comorbidity was reported less 
often [6, 13], and that the patient’s preference was also 
a common reason for withholding adjuvant chemother-
apy (no difference between diabetic and non-diabetic 
patients) [14].
Some studies have investigated the recurrence rate 
and OS for colon cancer in diabetic patients, but the 
results are confl icting [5, 7, 15]. In contrast to our 
study, Meyerhardt and colleagues reported poorer 
recurrence-free survival and higher colon cancer 
recurrence rates for diabetic patients than for non-
diabetic patients. A possible explanation for this 
difference might be the longer follow-up in their study 
(mean 4 years in our study compared with 9.4 years 
in their study). Moreover, in the study by Meyerhardt 
and colleagues, the recurrence from colon cancer was 
especially high for diabetic patients after 4 years. In 
contrast to other studies, we did not fi nd a statistically 
signifi cant effect of diabetes on OS [5, 7, 15]. These 
studies, however, also had larger study populations and 
longer durations of follow-up. In addition, some of 
these studies included patients with both stage II and 
III colon cancer, whereas we only included stage III. 
The effect of diabetes on outcome of colon cancer was 
shown to be most evident for diabetic patients with 
stage II colon carcinoma [5, 15]. A possible stage-de-
pendent effect needs further research. Another likely 
explanation for these confl icting results is that OS 
for diabetic patients is partly affected by comorbidi-
ties. In our study, diabetic patients had signifi cantly 
Without diabetes, no chemotherapy
With diabetes, no chemotherapy
Without diabetes, chemotherapy
With diabetes, chemotherapy
100
80
60
40
%
20
0
0 6 12 18 24 30 36 42 4
8 54 60
Month after diagnosis
Disease free survival for patients with and without diabetes
with and without chemotherapy
Figure 2 Disease-free survival for colon cancer patients with and without diabetes, according to chemotherapy.
Table 6 Medication for diabetes before and 1 year after colon cancer 
diagnosis.
Medication Frequency (%)
Before diagnosis After diagnosis
Diet 9 (5) 9 (5)
Oral antiglycaemic agent 135 (67) 97 (48)
Insulin 43 (21) 44 (22)
Insulin and oral antiglycaemic agent 9 (5) 10 (5)
Unknown or not applicable 3 (2) 41 (20)
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more comorbidities than non-diabetic patients, and 
previous studies have also shown that comorbidities 
negatively infl uence colon cancer prognosis [9, 16]. 
Moreover, previous studies that reported a worse OS 
for diabetic patients did not correct for comorbidities 
[5, 15]. 
In contrast to other studies that reported on sur-
vival of colon cancer in diabetic patients, we also 
studied the effect of diabetes-related prognostic var-
iables on survival from colon cancer. The extent of 
diabetes in terms of duration or glycaemic control 
is possibly an important factor for colon cancer sur-
vival. Hyperinsulinaemia is prospectively related 
to colon cancer risk, distant recurrence, and death 
in cancer patients and higher mortality in diabetic 
patients [17–20]. This could imply that diabetic 
patients with high insulin might have a worse can-
cer-specifi c prognosis. We did not fi nd a statistically 
signifi cant effect of these variables on OS. However, 
data for these variables were incomplete and further 
research on these effects is necessary. According to 
in vitro and in vivo studies, metformin could have a 
positive effect on OS in cancer patients with diabetes 
and colorectal cancer, in particular [21–23]. We also 
found lower all-cause mortality in patients who used 
metformin, but this result was not signifi cant, possibly 
due to the small study population (HR 0.73; 95% CI 
0.49–1.11). However, this could have infl uenced OS 
in colon cancer patients with diabetes compared with 
non-diabetic patients. 
Whether diabetes independently infl uences chemo-
therapy-related complications is doubtful. In our study, 
diabetic patients did not have more side-effects from 
adjuvant chemotherapy compared with non-diabetic 
patients. This is in line with the fi ndings of an observa-
tional study of Gross and colleagues who reported that 
diabetic patients were not more frequently hospitalized 
for chemotherapy-related complications. In contrast, a 
previous randomized trial of colon cancer patients who 
received adjuvant chemotherapy found signifi cantly 
more treatment-related diarrhoea in diabetic patients 
[5]. Although we did not fi nd a higher risk of toxic-
ity from chemotherapy in diabetic patients, we did 
fi nd a higher rate of postoperative complications and 
more frequent admissions to the intensive care unit in 
diabetic colon cancer patients. Diabetic patients may 
be more prone to these complications because of bad 
wound healing and a weaker immune system [24–26]. 
Moreover, this could imply that complications are more 
severe in diabetic patients. 
This is the fi rst study that has investigated the asso-
ciation between diagnosis/treatment of colon cancer 
and the course of diabetes. HbA1c was signifi cantly 
lower after diagnosis of colon cancer than before diag-
nosis of colon cancer (mean HbA1c 7.2 vs. 7.6%). This 
might suggest a favourable effect of colon cancer and 
its treatment on glycaemic control. A possible expla-
nation is a better follow-up of patients after colon 
cancer since a substantial proportion of patients had 
higher dose medication for diabetes after colon cancer 
diagnosis. In addition, weight loss because of colon 
cancer and its treatment could lead to lower HbA1c 
levels.
We should keep in mind that this is a retrospective 
observational study in which there was selection of the 
fi ttest patients for treatment. Although we corrected for 
the known confounders functional status and comorbid-
ity, confounding by indication could have resulted in a 
shorter OS of patients not receiving adjuvant chemo-
therapy because of unmeasured confounding factors that 
contraindicated chemotherapy.
The strength of this study was a broad data collec-
tion that included specifi c information about patients, 
diseases, and treatment-related characteristics. Also, our 
study included unselected patients, which refl ects daily 
clinical practice. Although not all data were available for 
all patients, this is the fi rst study to describe the asso-
ciation between diagnosis/treatment of colon cancer and 
the course of diabetes. 
In conclusion, diabetic patients did not have more 
side-effects due to adjuvant chemotherapy, adjuvant 
chemotherapy had a positive effect on survival for both 
patients with and without diabetes, and diabetes control 
remained good after treatment for cancer. Therefore, 
diabetes alone is not a reason for withholding adjuvant 
chemotherapy. Further prospective research should con-
fi rm these results.
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